Lixte Presents Positive Results For LB-1.2 Trial

National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) and National Institutes of Health have reported that Lixte’s novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers.

The research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte.

John Kovach, President and CEO of Lixte, said: LB-1.2 exerts anti-cancer activity directly on the cancer cell and more dramatically, by preventing cancer cells from recovering from DNA-damage produced by standard anti-cancer drugs. In mouse models, LB-1.2 plus Temozolomide caused complete regression without recurrence in 50 % of animals bearing tumors of human glioblastoma multiforme and also, marked regression of neuroblastoma. Temozolomide, the standard drug for the treatment of patients with GBM, by itself caused regression but with recurrence of all tumors.

“Since LB-1.2 has a biochemical action similar to an older drug used for anticancer treatment for many years in China, we are cautiously optimistic that LB-1.2 will be well tolerated by cancer patients and hopefully, will potentially be as effective as it is in animal models of human cancer. We believe that adding LB-1.2 may be a general method for improving the effectiveness of several standard anticancer drugs not only against tumors of the brain and neural tissue but also against other cancers sensitive to drugs that work by damaging DNA. Safety, of course, must be demonstrated first in animal studies and subsequently in Phase I clinical trials before evaluation of therapeutic effectiveness can be assessed against different cancer types in patients, he added.